Cargando…
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
PURPOSE: Intratumoral interleukin-2 (IL-2) is effective but does not generate systemic immunity. Intravenous ipilimumab produces durable clinical response in a minority of patients, with potentially severe toxicities. Circulating anti-tumor T cells activated by ipilimumab may differ greatly from tum...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325451/ https://www.ncbi.nlm.nih.gov/pubmed/27391442 http://dx.doi.org/10.18632/oncotarget.10453 |